ArticleJournal of ginseng research2026
Effect of red ginseng beverage on menopausal symptoms in Chinese women: A randomized, double-blind, placebo-controlled clinical trial.
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Menopause involves both physical and psychological changes, notably vasomotor and mood symptoms. Menopausal symptoms adversely affect women's quality of life and work. This study evaluates the effects of red ginseng beverage (RGB) on menopausal symptoms in Chinese women. Methods: This 90-day, randomized, double-blind, placebo-controlled trial involved 112 eligible women assigned to either an RGB or placebo group. Primary outcomes were the Kupperman Index. Secondary outcomes included vasomotor markers, psychological assessments, lipid profiles, exercise-induced fatigue test indicators and safety indicators. Safety assessments included fire-heat symptom scale, female hormone levels, endometrial thickness, breast ultrasound, and standard laboratory tests. All outcomes were assessed at baseline and upon study completion. Results: RGB group primary outcomes compared to placebo: (1) the Conclusion: These findings demonstrate RGB's efficacy and safety for menopausal symptom management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.